| Schedule of Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended June 30, 2024 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
14,855 |
|
$ |
41 |
|
$ |
14,896 |
Cost of goods - product revenue |
|
|
(6,541) |
|
|
— |
|
|
(6,541) |
Research and development |
|
|
(913) |
|
|
(11,758) |
|
|
(12,671) |
Selling, general and administrative |
|
|
(10,328) |
|
|
(10,495) |
|
|
(20,823) |
Asset impairment |
|
|
— |
|
|
(2,649) |
|
|
(2,649) |
Other expense |
|
|
(434) |
|
|
(602) |
|
|
(1,036) |
Segment loss |
|
$ |
(3,361) |
|
|
(25,463) |
|
$ |
(28,824) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Six Months Ended June 30, 2024 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
27,885 |
|
$ |
41 |
|
$ |
27,926 |
Cost of goods - product revenue |
|
|
(13,357) |
|
|
(0) |
|
|
(13,357) |
Research and development |
|
|
(8,797) |
|
|
(28,698) |
|
|
(37,495) |
Selling, general and administrative |
|
|
(18,748) |
|
|
(20,029) |
|
|
(38,777) |
Asset impairment |
|
|
— |
|
|
(2,649) |
|
|
(2,649) |
Other expense |
|
|
(786) |
|
|
(2,708) |
|
|
(3,494) |
Segment loss |
|
$ |
(13,803) |
|
$ |
(54,043) |
|
$ |
(67,846) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Three Months Ended June 30, 2023 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
17,172 |
|
$ |
214 |
|
$ |
17,386 |
Cost of goods - product revenue |
|
|
(7,767) |
|
|
— |
|
|
(7,767) |
Research and development |
|
|
(1,774) |
|
|
(30,368) |
|
|
(32,142) |
Selling, general and administrative |
|
|
(12,141) |
|
|
(12,298) |
|
|
(24,439) |
Asset impairment |
|
|
(3,143) |
|
|
— |
|
|
(3,143) |
Other expense |
|
|
(710) |
|
|
(8,486) |
|
|
(9,196) |
Segment loss |
|
$ |
(8,363) |
|
$ |
(50,938) |
|
$ |
(59,301) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
Six Months Ended June 30, 2023 |
|
Sales |
|
Development |
|
Consolidated |
Net revenue |
|
$ |
29,385 |
|
$ |
430 |
|
$ |
29,815 |
Cost of goods - product revenue |
|
|
(14,216) |
|
|
— |
|
|
(14,216) |
Research and development |
|
|
(3,807) |
|
|
(67,841) |
|
|
(71,648) |
Selling, general and administrative |
|
|
(25,433) |
|
|
(24,347) |
|
|
(49,780) |
Asset impairment |
|
|
(3,143) |
|
|
— |
|
|
(3,143) |
Other expense |
|
|
(1,285) |
|
|
(4,189) |
|
|
(5,474) |
Segment loss |
|
$ |
(18,499) |
|
$ |
(95,947) |
|
$ |
(114,446) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
June 30, 2024 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
18,658 |
|
$ |
— |
|
$ |
18,658 |
Tangible assets |
|
|
46,531 |
|
|
80,496 |
|
|
127,027 |
Total segment assets |
|
$ |
65,189 |
|
$ |
80,496 |
|
$ |
145,685 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
|
|
|
|
|
|
and |
|
|
|
|
|
Dermatology |
|
Biotechnology |
|
|
|
|
|
Products |
|
Product |
|
|
|
December 31, 2023 |
|
Sales |
|
Development |
|
Total Assets |
Intangible assets, net |
|
$ |
20,287 |
|
$ |
— |
|
$ |
20,287 |
Tangible assets |
|
|
56,562 |
|
|
90,677 |
|
|
147,239 |
Total segment assets |
|
$ |
76,849 |
|
$ |
90,677 |
|
$ |
167,526 |
|